Although alpha interferons have demonstrable antitumour activity, for most neoplasms, responses have not proven better than currently available chemotherapy (Silver, 1985) . This modest response rate could improve with the identification of optimal doses and schedules extrapolated from knowledge of basic cellular antitumour activity. Unfortunately, investigators have been unable to identify the clinically significant mechanisms of antitumour action from among known interferon biological effects. The latter include direct intracellular and membrane effects, possibly related to oncogene expression or related growth regulators; and indirect host mediated activity, probably related to immune function. The problem is important, since there is evidence that a very different dose strategy would be appropriate to take advantage of direct as opposed to indirect interferon mechanisms of action (Golub et al., 1982; Salmon et al., 1983) . In the absence of this basic information an in vitro assay of relevant biomodulatory activity would help establish an optimal dose schedule.
The objectives of our prospectively randomized study of a high vs. low dose treatment strategy were: to assess toxicity, compare clinical effectiveness, and evaluate in vitro immune function studies as biomodulatory correlates of clinical activity. An evaluation of toxicity and an analysis of lymphocyte subsets has been reported on earlier groups of patients (Silver et al., 1983 .
Materials and methods

Patient selection
To be considered for treatment histopathologic confirmation of diagnosis was required with a measurable component of disease, and no history of a second malignancy. Interferon was offered only following a trial of known effective firstline hormonal or chemotherapy and after at least two weeks had elapsed since discontinuance of previous treatment. The minimum age was 21. Although there was no upper age limit, patients were required to have an ECOG ( The low dose strategy (LDS) was devised to take advantage of indirect antitumour activity through the stimulation of host immunity as reported for such treatment (Golub et al., 1982; Gresser et al., 1972) , and provides a basis for comparison with other alpha interferon studies (Borden et al., 1982; Krown et al., 1984) . Patients received 2 M units m-2 interferon alpha-Ni (Wellferon'h'; Burroughs Wellcome, Kent, UK) daily by intramuscular injection for an induction period of 28 days. In the absence of disease progression, treatment was then continued daily for 7 days on alternate weeks until evidence of progression.
High dose strategy (HDS) treatment was based on laboratory data suggesting that relatively high doses provided the optimal conditions for direct tumour cytotoxicity (Salmon et al., 1983) . Because of a wide discrepancy in reported tolerance (Priestman, 1980; Rohatiner et al., 1982) an escalating schedule was selected to allow for possible individual variation. As previously detailed (Silver et al., 1983 , interferon was given by continuous i.v. infusion to provide intense sustained exposure. The 10 day induction treatment began at 5 M unitsm-2day-1, with subsequent daily escalation of 5M unitsm-2day-1 to a total of 20M unitsm -2, then further escalation every other day as tolerated. In the absence of disease progression at 28 days, patients had repeat maintenance infusions for the first 10 days of each 28 day cycle. On day 1 of the second and each subsequent treatment cycle, patients received one-half of the maximal tolerated dose of the previous treatment followed by escalation to the previous maximal tolerated dose on the second day if < 20M units m-2 or on the third day if > 20M units m-2. Further escalation continued as described above.
For either treatment arm, interferon was reduced by 50% for total granulocyte values of <800 mm-3 or platelet counts of <00,000 mm-3, and treatment was interrupted for granulocytes of < 500 mm-3 or platelets of < 50,000 mm -. Reduction or interruption of treatment could also be at the discretion of the treating physician for unexpected toxicity.
Blood collection
Haematologic and biochemical test panels were performed at least 3 times per week. Blood collection for lymphocyte studies was performed pretreatment, 6h after the 8th, 15th and 22nd daily induction interferon injections for LDS patients followed by pretreatment and 6 h after the 7th injection of each maintenance cycle. For HDS patients, samples were obtained pretreatment, on day 8 (during infusion) and day 15 (off infusion) for each 28 day cycle. The procedure for preparing defibrinated blood and isolating peripheral blood lymphocytes (PBL) has been described in detail (Silver et al., 1983 (Silver et al., 1983) .
NK cytotoxicity assay A 51Cr release assay was performed as previously described (Silver et al., 1983) . Briefly, K562 target cells were subcultured 24-48 h prior to study, then 1.5 x 106 viable cells were washed and exposed to 0.1 mCi 51Cr. The reaction mixture, prepared in triplicate, consisted of 104 target cells and 2.5 x 105 lymphocytes. After 4 h incubation at 37°C and centrifugation, the radioactivity of supernatant aliquots was determined. Percentage cytotoxicity was calculated from: (experimental release-spontaneous release)/(maximum release-spontaneous release) x 100. Analysis of assay variation and possible systematic error were as previously described (Silver et al., 1983 Lymphocyte data were evaluated from the perspective of two time periods: over the total time on study and during each individual period of interferon administration. For the latter analysis the results for the first treatment were excluded since the timing for HDS and LDS were not comparable in that case. When examining intergroup correlations and trend over total time on study, all values for each patient were subjected to analysis of covariance to test for significant changes over time while controlling for individual variation. Analysis of variance was used to test for change during the shorter period of each interferon administration.
Results
A total of 62 patients were entered on study. Of these, 9 were not evaluable for response. One patient had not met eligibility requirements, was inappropriately randomized and did not receive interferon. Eight (3 LDS, 5 HDS) could not tolerate the first course (10 days) of treatment and, as previously specified in the protocol, were evaluable for toxicity, but not response. Intolerance was directly related to interferon effects in 3 of the 8 patients (1 each with severe thrombocytopenia, granulocytopenia and fatigue). Interferon induced fatigue, immobility in bed and hypotension may have contributed to development of multiple pulmonary emboli in a high risk patient. All patients were closely monitored for coagulopathy, but none was detected (Silver et al., 1985) . Complications of unanticipated extensive or rapidly progressive disease intervened in 4 patients.
We have previously reported a detailed evaluation of dose tolerance and toxicity in the first 37 patients entered on study . For (Table II) . There were only 2 partial responses lasting 18 and 44 weeks. Improvement in survival for HDS patients could clearly not be related to partial or complete responses. To evaluate a possible contribution of lesser responses, we grouped minimal measurable with partial responders and compared these total responders with the remaining non-responsive patients. There was an overall trend of improved response for HDS compared with LDS patients, but this was not statistically significant. For the breast carcinoma subgroup, however, there was a significantly higher response rate for the HDS (P = 0.03, chi square).
There was evidence of a relationship between hormone response and interferon response among breast carcinoma patients. For the subgroup of 21 patients with assessable response to previous hormone therapy, those that had responded to hormonal manipulation also tended to respond to interferon (P=0.005, chi square). This result could in part be related to dose, since hormone responders were overrepresented in the HDS arm (P= 0.03). To examine this Immune effects Immune function data revealed additional relationships for dose strategy and response. Over the short 7-8 day sampling period during each interferon administration there were no trends suggesting immune stimulation. There was a trend for MLC and PHA suppression and this was significantly more marked for HDS (MLC P=0.002; PHA P=0.05). Over the longer term total time on study there were significant immune effects. For HDS patients there was a significant increase in the number of CD2 + (sheep red blood cell binding) cells and CD4+ (helper-inducer/suppressor-inducer) cells along with enhanced activity of NK and MLC (Table  III) . A similar pattern was seen for responding patients where there was an increase in CD2 + and CD4 + cells and augmented PHA activity. The only significant change for LDS and non-responding patients was a decrease in total lymphocytes. In comparing dose strategies, HDS patients developed significantly more MLC activity and LDS patients showed a significantly greater reduction in total lymphocytes (Table IV) . Responders were distinguished from nonresponders by having developed significantly more MLC and PHA activity. study is as described in our preliminary analysis of the first 37 patients . Although significant side effects were seen for both dose strategies, these were certainly milder than routinely encountered with many combination chemotherapy programs. In addition to the reported major toxicities of fever, fatigue, and leukopenia, we encountered hypotension more frequently than has been previously reported, and this was clearly related to dose. We also found wide individual variation in tolerance to the HDS, strongly supporting the use of dose escalation if this strategy is to be used.
Early reports of encouraging objective response rates for alpha interferons in breast carcinoma (Borden et al., 1982; Gutterman et al., 1980) have not been repeated in our own experience (Table II) . This discrepancy may in part reflect the predominance in our study of late stage patients. Even with the expectation of an improved response for more limited disease, it appears unlikely that using alpha interferons as first-line agents will yield response rates comparable to current combination chemotherapy. Few (Friedman, 1986) . Such modulation of growth and differentiation suggests that the antitumour action of interferons may be more like that of hormones than chemotherapeutic agents. In our study it is interesting that patients whose tumours were sensitive to hormonal manipulation also tended to respond to interferon and experienced improved survival.
In experimental systems the antitumour effects of interferon can be mediated indirectly through stimulation of host immunity (Gresser et al., 1972) . Comparable evidence in humans has been inconsistent, perhaps partly because of an emphasis on the more transient effects of interferons over hours or days. This corresponds to our own experience over the shorter term, where there was no indication of immune stimulation. The trend of decreased PHA and MLC during the short intermittent intervals of interferon administration may be best explained by interferon antiproliferative effects (Hokland et al., 1983) . We were particularly interested in longer term trends which would have a greater probability of being clinically significant. Over the extended period of total time on study there was evidence of immunostimulation for HDS and responders. (Silver et al., 1983) , but unexpected on the basis of earlier published results (Golub et al., 1982; Koren et al., 1983; Maluish et al., 1983) . However, our findings have more recently gained support from others (Neefe et al., 1986; Medenica & Slack, 1985) .
Since the same intermittent high dose treatment strategy resulted in both the immune effects and superior survival, it is possible that the augmented immune status was responsible for improved clinical outcome. If so, it is remarkable that this might have been accomplished with relatively modest absolute changes in lymphocyte values in patients with advanced disease. The immediate importance of this association of a biomodulatory effect with clinical response may be its potential as a tool for identifying optimal dose and schedules for treatment.
In our experience, interferon has limited activity as a single agent in advanced breast and ovary carcinoma. Since effective chemotherapy is already available for these conditions, the clinical potential for interferon lies in combination with other agents and employment earlier in the course of disease. There is evidence that interferon in combination with chemotherapy agents or other biologicals can be synergistic (Fleischmann et al., 1984; Namba et al., 1983) . Our data indicate that the usual chemotherapy response criteria are not as relevant for biological therapy, and that more attention needs to be directed at survival analysis.
In ongoing studies we are evaluating more practical schedules of high dose intermittent therapy, and the use of interferon in combination with chemotherapy (Connors & Silver, 1984) . We will further examine biomodulatory effects to determine if they predict positive treatment outcome.
